In Depth Research on Global Cancer Antibody Drug Conjugates Market and Pipeline Insight 2022

“Global Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022” report highlights:

* Impetus of Antibody Drug Conjugates
* Mechanism of Cancer Antibody Drug Conjugates
* Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
* Marketed Cancer Antibody Drug Conjugate Clinical Insight
* Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication , Mode of Action, Formulation and Phase

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugates-market-and-pipeline-insight-2022.php

Table of Contents

Impetus of Antibody Drug Conjugates
1.1 Prologue to Cancer Antibody Drug Conjugate
1.2 The ABCs of ADCs

Structural Entities of Antibody Drug Conjugate
2.1 Rational Design of Antibody Drug Conjugates
2.1.1 Monoclonal Antibody
2.1.2 Linker
2.1.3 Drug Payload
2.2 Aspects of Conjugational Chemistry

Revolutionizing Antibody Drug Conjugates Generation
3.1 First and Second Generation ADCs
3.2 Third Generation ADCs

Mechanism of Cancer Antibody Drug Conjugates
4.1 Sequential Therapeutic Mechanism for Cancer
4.1.1 Selecting an Appropriate Target
4.1.2 Antigen Binding Complex
4.1.3 Antibody Drug Conjugate Internalization
4.2 Approved Antibody Drug Conjugate

Global Cancer Antibody Drug Conjugates Market Overview

Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
6.1 Phase
6.2 Indication
6.3 Mechanism of Action
6.4 Company
6.5 Formulation

Global Cancer Antibody Drug Conjugates Market Dynamics
7.1 Favorable Market Parameters
7.2 Commercialization Challenges

Global Cancer Antibody Drug Conjugates Market Future Prospects
8.1 Approaching Newer Approaches
8.2 Upcoming Future Market Prospects

Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration

Marketed Cancer Antibody Drug Conjugate Clinical Insight
10.1 Brentuximab Vedotin (Adcetris)
10.2 Mifamurtide (Junovan and Mepact)
10.3 Gemtuzumab Ozogamicin (Mylotarg)
10.4 Trastuzumab Emtansine (Kadcyla)
10.5 Ibritumomab Tiuxetan (Zevalin and Zevamab)
10.6 Satumomab (OncoScint CR/OV)

Competitive Landscape
11.1 AbbVie
11.2 AbGenomics Corporation
11.3 Biogen Idec
11.4 Biotest
11.5 Bristol-Myers Squibb
11.6 Celldex Therapeutics Inc
11.7 Helix BioPharma
11.8 IBC Pharmaceuticals
11.9 ImmunoGen
11.10 Immunomedics
11.11 Merck
11.12 Millennium
11.13 Nordic Nanovector
11.14 Novartis
11.15 PDL BioPharma
11.16 Progenics Pharmaceuticals
11.17 Roche
11.18 Seattle Genetics
11.19 Stem CentRx
11.20 UCB
11.21 Viventia Biotechnologies

Figure 1-1: Advantages of Antibody Drug Conjugates
Figure 2-1: Detailed Structure of Antibody Drug Conjugate
Figure 2-2: Components of Antibody Drug Conjugates
Figure 2-3: Categorization of the Types of Linkers
Figure 2-4: Conjugation Strategies Adopted for Antibody Drug Conjugate
Figure 3-1: Difference Between First and Second Generation Antibody Drug Conjugate
Figure 3-2: Major Challenges of the Second Generation Antibody Drug Conjugate
Figure 4-1: Mechanism of Antibody Drug Conjugate
Figure 4-2: Mechanism of Brentuximab Vedotin
Figure 4-3: Mechanism of Trastuzumab Emtansine
Figure 5-1: Global - Antibody Drug Conjugates Market (US$ Billion), 2014-2022
Figure 5-2:Global - Adcetris Sales (Million US$), 2016-2022
Figure 5-3: Global - Kadcyla Sales (Million US$), 2016-2022
Figure 5-4: Global - Kadcyla Sales by Region (%), 2016
Figure 6-1: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (%), 2017 till 2022
Figure 6-2: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (Number), 2017 till 2022
Figure 6-3: Global - Cancer Antibody Drug Conjugates Pipeline By Indication (Number), 2017 till 2022
Figure 6-4: Global - Cancer Antibody Drug Conjugates Pipeline By Mode of Action (Number), 2017 till 2022
Figure 6-5: Global - Cancer Antibody Drug Conjugates Pipeline By Company (Number), 2017 till 2022
Figure 6-6: Global - Cancer Antibody Drug Conjugates Pipeline By Formulation (Number), 2017 till 2022
Figure 7-1: Antibody Drug Conjugates Market Favorable Parameters
Figure 7-2: Major Challenges Faced by Antibody Drug Conjugate Market
Figure 11-1:AbGenomics - Clinical Pipeline
Figure 11-2: Celldex - Clinical Pipeline
Figure 11-3: Merck - Clinical Pipeline
Figure 11-4: Millennium - Clinical Pipeline
Figure 11-5: Novartis - Clinical Pipeline
Figure 11-6: Progenics - Clinical Pipeline
Figure 11-7: Roche - Clinical Pipeline
Figure 11-8: Seattle Genetics - Clinical Pipeline
Figure 11-9: Viventia - Clinical Pipepline

Table 4-1: FDA Approved Antibody Drug Conjugate For Cancer
Table 4-2: Some of the Antibody Drug Conjugates under Development
Table 5-1: Drugs for Treatment of HER2-Positive Breast Cancer

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.